Publications

Phase Ii, Multicenter, Single-Arm Trial of Eribulin as First-Line Therapy for Patients With Aggressive Taxane-Pretreated Her2-Negative Metastatic Breast Cancer: The Meribel Study

AuthID
P-00Q-4Y2

Author(s)

Ortega, V

Anton, A

Garau, I

Afonso, N

Calvo, L

Fernandez, Y

Martinez Garcia, M

Blanco, E

Zamora, P

Garcia, M

Juan Illarramendi, JJ

Rodrguez Sanchez, CAR

Sampayo, M

Aguirre, E

Manuel Perez Garcia, JM

Cortes, J

Llombart Cussac, A

Document Type

Article

Year published

2019

Published

in CLINICAL BREAST CANCER, ISSN: 1526-8209

Volume: 19, Issue: 2, Pages: 105-112 (8)

Indexing

Wos^®

Scopus^®

Google Scholar^®

Publication Identifiers

DOI: 10.1016/j.clbc.2018.12.012

Scopus: 2-s2.0-85060147511

Wos: WOS:000462167800019

Source Identifiers

ISSN: 1526-8209

Export Publication Metadata

Marked List

Add to Marked List

Citations

Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

CORE Conference

No information about CORE Rank

During the preprocessing phase, only publications of type 'Proceedings Paper' or 'Proceedings' are automatically processed to identify their CORE Rank.

TIP: If your publication's CORE Rank is missing, you can contact with your institutional manager to have the correct ranking manually added to the record.

Journal Factors

Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

Full Text

Full Text @ sfx.b-on.pt

Phase Ii, Multicenter, Single-Arm Trial of Eribulin as First-Line Therapy for Patients With Aggressive Taxane-Pretreated Her2-Negative Metastatic Breast Cancer: The Meribel Study

Useful Links

Get Help

Federated Authentication (Click on the image)

Phase Ii, Multicenter, Single-Arm Trial of Eribulin as First-Line Therapy for Patients With Aggressive Taxane-Pretreated Her2-Negative Metastatic Breast Cancer: The Meribel Study

Useful Links

Get Help